IBDEI0L5 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10019,1,3,0)
 ;;=3^Diabetic Retinopathy Nos
 ;;^UTILITY(U,$J,358.3,10019,1,4,0)
 ;;=4^362.01
 ;;^UTILITY(U,$J,358.3,10019,2)
 ;;=^12257
 ;;^UTILITY(U,$J,358.3,10020,0)
 ;;=362.02^^44^560^72
 ;;^UTILITY(U,$J,358.3,10020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10020,1,3,0)
 ;;=3^Prolif Diab Retinopathy
 ;;^UTILITY(U,$J,358.3,10020,1,4,0)
 ;;=4^362.02
 ;;^UTILITY(U,$J,358.3,10020,2)
 ;;=^268610
 ;;^UTILITY(U,$J,358.3,10021,0)
 ;;=362.03^^44^560^64
 ;;^UTILITY(U,$J,358.3,10021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10021,1,3,0)
 ;;=3^Nonprolf Db Retnoph Nos
 ;;^UTILITY(U,$J,358.3,10021,1,4,0)
 ;;=4^362.03
 ;;^UTILITY(U,$J,358.3,10021,2)
 ;;=^332786
 ;;^UTILITY(U,$J,358.3,10022,0)
 ;;=362.04^^44^560^61
 ;;^UTILITY(U,$J,358.3,10022,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10022,1,3,0)
 ;;=3^Mild Nonprolf Db Retnoph
 ;;^UTILITY(U,$J,358.3,10022,1,4,0)
 ;;=4^362.04
 ;;^UTILITY(U,$J,358.3,10022,2)
 ;;=^332787
 ;;^UTILITY(U,$J,358.3,10023,0)
 ;;=362.05^^44^560^62
 ;;^UTILITY(U,$J,358.3,10023,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10023,1,3,0)
 ;;=3^Mod Nonprolf Db Retinoph
 ;;^UTILITY(U,$J,358.3,10023,1,4,0)
 ;;=4^362.05
 ;;^UTILITY(U,$J,358.3,10023,2)
 ;;=^332788
 ;;^UTILITY(U,$J,358.3,10024,0)
 ;;=362.06^^44^560^98
 ;;^UTILITY(U,$J,358.3,10024,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10024,1,3,0)
 ;;=3^Sev Nonprolf Db Retinoph
 ;;^UTILITY(U,$J,358.3,10024,1,4,0)
 ;;=4^362.06
 ;;^UTILITY(U,$J,358.3,10024,2)
 ;;=^332789
 ;;^UTILITY(U,$J,358.3,10025,0)
 ;;=379.27^^44^560^103
 ;;^UTILITY(U,$J,358.3,10025,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10025,1,3,0)
 ;;=3^Vitreomacular Adhesion
 ;;^UTILITY(U,$J,358.3,10025,1,4,0)
 ;;=4^379.27
 ;;^UTILITY(U,$J,358.3,10025,2)
 ;;=^340517
 ;;^UTILITY(U,$J,358.3,10026,0)
 ;;=115.02^^44^560^44
 ;;^UTILITY(U,$J,358.3,10026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10026,1,3,0)
 ;;=3^Histoplasma Capsulatum Retinitis
 ;;^UTILITY(U,$J,358.3,10026,1,4,0)
 ;;=4^115.02
 ;;^UTILITY(U,$J,358.3,10026,2)
 ;;=^266890
 ;;^UTILITY(U,$J,358.3,10027,0)
 ;;=190.5^^44^560^58
 ;;^UTILITY(U,$J,358.3,10027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10027,1,3,0)
 ;;=3^Malig Retina
 ;;^UTILITY(U,$J,358.3,10027,1,4,0)
 ;;=4^190.5
 ;;^UTILITY(U,$J,358.3,10027,2)
 ;;=^73530
 ;;^UTILITY(U,$J,358.3,10028,0)
 ;;=198.4^^44^560^59
 ;;^UTILITY(U,$J,358.3,10028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10028,1,3,0)
 ;;=3^Malig Secondary Choroid
 ;;^UTILITY(U,$J,358.3,10028,1,4,0)
 ;;=4^198.4
 ;;^UTILITY(U,$J,358.3,10028,2)
 ;;=^267335
 ;;^UTILITY(U,$J,358.3,10029,0)
 ;;=200.00^^44^560^81
 ;;^UTILITY(U,$J,358.3,10029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10029,1,3,0)
 ;;=3^Reticulosarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,10029,1,4,0)
 ;;=4^200.00
 ;;^UTILITY(U,$J,358.3,10029,2)
 ;;=^72635
 ;;^UTILITY(U,$J,358.3,10030,0)
 ;;=228.03^^44^560^38
 ;;^UTILITY(U,$J,358.3,10030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10030,1,3,0)
 ;;=3^Hemangioma Retina
 ;;^UTILITY(U,$J,358.3,10030,1,4,0)
 ;;=4^228.03
 ;;^UTILITY(U,$J,358.3,10030,2)
 ;;=^267700
 ;;^UTILITY(U,$J,358.3,10031,0)
 ;;=228.09^^44^560^39
 ;;^UTILITY(U,$J,358.3,10031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10031,1,3,0)
 ;;=3^Hemangioma,Oth Sites
 ;;^UTILITY(U,$J,358.3,10031,1,4,0)
 ;;=4^228.09
 ;;^UTILITY(U,$J,358.3,10031,2)
 ;;=^55270
 ;;^UTILITY(U,$J,358.3,10032,0)
 ;;=360.00^^44^560^73
 ;;^UTILITY(U,$J,358.3,10032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10032,1,3,0)
 ;;=3^Purulent Endophthalmitis,Unspec
 ;;^UTILITY(U,$J,358.3,10032,1,4,0)
 ;;=4^360.00
 ;;
 ;;$END ROU IBDEI0L5
